Oncology Department, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei Economic and Technological Development Zone, Hefei 230601, China.
Hefei Comprehensive National Science Center, Institute of Energy, Building 9, Binhu Excellence City Phase I, 16 Huayuan Avenue, Baohe District, Hefei 230031, China.
Curr Oncol. 2022 Oct 18;29(10):7868-7886. doi: 10.3390/curroncol29100622.
Boron neutron capture therapy (BNCT) is a binary modality that is used to treat a variety of malignancies, using neutrons to irradiate boron-10 (B) nuclei that have entered tumor cells to produce highly linear energy transfer (LET) alpha particles and recoil Li nuclei (B [n, α] Li). Therefore, the most important part in BNCT is to selectively deliver a large number of B to tumor cells and only a small amount to normal tissue. So far, BNCT has been used in more than 2000 cases worldwide, and the efficacy of BNCT in the treatment of head and neck cancer, malignant meningioma, melanoma and hepatocellular carcinoma has been confirmed. We collected and collated clinical studies of second-generation boron delivery agents. The combination of different drugs, the mode of administration, and the combination of multiple treatments have an important impact on patient survival. We summarized the critical issues that must be addressed, with the hope that the next generation of boron delivery agents will overcome these challenges.
硼中子俘获治疗（BNCT）是一种二元治疗模式，用于治疗各种恶性肿瘤，利用中子照射进入肿瘤细胞的硼-10（B）原子核，产生高传能线密度（LET）的阿尔法粒子和反冲锂原子核（B[n,α]Li）。因此，BNCT 中最重要的部分是选择性地将大量 B 递送到肿瘤细胞中，而只有少量递送到正常组织中。到目前为止，BNCT 已在全球超过 2000 例病例中使用，BNCT 治疗头颈部癌症、恶性脑膜瘤、黑色素瘤和肝细胞癌的疗效已得到证实。我们收集和整理了第二代硼递药剂的临床研究。不同药物的联合使用、给药方式以及多种治疗方法的联合使用对患者的生存有重要影响。我们总结了必须解决的关键问题，希望下一代硼递药剂能够克服这些挑战。
